Compare AJANTA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA VENUS REMEDIES AJANTA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 23.0 -1.1 - View Chart
P/BV x 4.1 0.1 5,125.7% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 AJANTA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
VENUS REMEDIES
Mar-18
AJANTA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,422126 1,129.4%   
Low Rs89861 1,469.1%   
Sales per share (Unadj.) Rs233.5301.8 77.4%  
Earnings per share (Unadj.) Rs44.0-24.9 -176.8%  
Cash flow per share (Unadj.) Rs52.22.5 2,049.6%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.1293.3 87.0%  
Shares outstanding (eoy) m88.0212.34 713.3%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.00.3 1,603.1%   
Avg P/E ratio x26.4-3.8 -701.7%  
P/CF ratio (eoy) x22.236.7 60.5%  
Price / Book Value ratio x4.50.3 1,426.1%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,0811,154 8,847.5%   
No. of employees `0006.80.9 735.1%   
Total wages/salary Rs m4,307393 1,095.7%   
Avg. sales/employee Rs Th3,022.64,026.1 75.1%   
Avg. wages/employee Rs Th633.4425.0 149.0%   
Avg. net profit/employee Rs Th569.1-331.8 -171.5%   
INCOME DATA
Net Sales Rs m20,5543,724 551.9%  
Other income Rs m21123 936.9%   
Total revenues Rs m20,7653,747 554.2%   
Gross profit Rs m5,664395 1,434.7%  
Depreciation Rs m721338 213.1%   
Interest Rs m12354 3.3%   
Profit before tax Rs m5,143-275 -1,868.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,27332 4,028.5%   
Profit after tax Rs m3,870-307 -1,260.9%  
Gross profit margin %27.610.6 260.0%  
Effective tax rate %24.8-11.5 -215.7%   
Net profit margin %18.8-8.2 -228.5%  
BALANCE SHEET DATA
Current assets Rs m11,8122,638 447.8%   
Current liabilities Rs m3,7762,305 163.9%   
Net working cap to sales %39.18.9 437.2%  
Current ratio x3.11.1 273.3%  
Inventory Days Days77135 57.1%  
Debtors Days Days8246 176.1%  
Net fixed assets Rs m14,3984,871 295.6%   
Share capital Rs m175123 142.1%   
"Free" reserves Rs m22,2773,496 637.3%   
Net worth Rs m22,4523,619 620.4%   
Long term debt Rs m71,374 0.5%   
Total assets Rs m26,9627,509 359.1%  
Interest coverage x444.30.2 199,276.4%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.80.5 153.7%   
Return on assets %14.40.6 2,280.4%  
Return on equity %17.2-8.5 -203.2%  
Return on capital %23.01.6 1,450.7%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m10,6820-   
Fx outflow Rs m2,102517 407.0%   
Net fx Rs m8,580-517 -1,661.1%   
CASH FLOW
From Operations Rs m3,748514 728.6%  
From Investments Rs m-2,228-123 1,809.9%  
From Financial Activity Rs m-1,475-387 380.9%  
Net Cashflow Rs m454 1,076.2%  

Share Holding

Indian Promoters % 73.8 32.9 224.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.2 861.1%  
FIIs % 7.6 0.6 1,310.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 66.4 25.6%  
Shareholders   20,968 20,121 104.2%  
Pledged promoter(s) holding % 4.4 36.4 12.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Climbs 975 Points Up; FMCG Stocks Fuel the Rally(09:30 am)

Asian share markets started higher on Monday on hopes of an interim Sino-US tariff deal after the two countries described their talks as "productive" and "constructive".

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 23, 2019 12:13 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS